Letybo (Botulinum Toxin Type A)

Botulinum toxin type A targets the SNAP‑25 protein in presynaptic nerve endings, cleaving it and blocking the release of acetylcholine. This interruption of neurotransmission prevents muscle contraction at the neuromuscular junction, resulting in temporary paralysis of the injected muscle and, when used in sweat glands, reduces secretory activity.

The dose of Letybo is individualized by the prescribing clinician based on the specific indication, muscle group, and patient characteristics. Dosing units are expressed in international units (U) and the exact amount, injection sites, and frequency are determined by the treating physician.

Safety data for Letybo in pregnancy and lactation are limited. The product should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by the prescriber after careful consideration of the clinical situation.

To request Letybo, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed) and necessary import documentation.

Letybo is a botulinum toxin type A formulation comparable to other branded products such as Botox® or Dysport®. While the core mechanism is the same, differences may exist in potency units, formulation excipients, and approved indications. Clinicians choose a product based on clinical experience, regulatory approvals, and specific patient needs.

Letybo should be stored at 2‑8 °C (refrigerated). Keep the vials in the original packaging, protect them from light, and avoid freezing or shaking. If the product reaches room temperature for a short period, it may be used promptly, but prolonged exposure should be avoided.

Letybo is administered by a trained healthcare professional via intramuscular injection. The injection technique, depth, and number of sites depend on the indication and target muscle group. Proper aseptic technique and accurate dosing are essential to achieve the desired therapeutic effect.

Serious risks include dysphagia, respiratory compromise, systemic spread of toxin leading to botulism‑like symptoms, severe allergic reactions, and unintended muscle weakness distant from the injection site. Patients should be monitored closely after injection, especially during the first few weeks, for any signs of these complications.

Letybo is contraindicated in individuals with a known hypersensitivity to botulinum toxin type A or any of its excipients, and in patients with active infection at the planned injection site. Caution is advised for those with neuromuscular disorders such as myasthenia gravis, Lambert‑Eaton syndrome, or ALS, as they may be more susceptible to adverse effects.